These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 9875140)
1. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140 [TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma? Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T J Pathol; 1999 May; 188(1):56-62. PubMed ID: 10398141 [TBL] [Abstract][Full Text] [Related]
5. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545 [TBL] [Abstract][Full Text] [Related]
6. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Redondo P; Lloret P; Idoate M; Inoges S Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689 [TBL] [Abstract][Full Text] [Related]
7. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229 [TBL] [Abstract][Full Text] [Related]
8. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396 [TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994 [TBL] [Abstract][Full Text] [Related]
10. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study. Crocetti E; Mangone L; Lo Scocco G; Carli P Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092 [TBL] [Abstract][Full Text] [Related]
11. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Väisänen A; Kuvaja P; Kallioinen M; Turpeenniemi-Hujanen T Hum Pathol; 2011 Aug; 42(8):1103-11. PubMed ID: 21334717 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Vasala K; Pääkko P; Turpeenniemi-Hujanen T Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455 [TBL] [Abstract][Full Text] [Related]
14. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831 [TBL] [Abstract][Full Text] [Related]
15. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282 [TBL] [Abstract][Full Text] [Related]
16. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. El-Shabrawi Y; Ardjomand N; Radner H; Ardjomand N J Pathol; 2001 Jun; 194(2):201-6. PubMed ID: 11400149 [TBL] [Abstract][Full Text] [Related]
17. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. Jones JL; Glynn P; Walker RA J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569 [TBL] [Abstract][Full Text] [Related]
18. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients]. de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183 [TBL] [Abstract][Full Text] [Related]
19. [Survival analysis in patients with cutaneous malignant melanoma]. Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233 [TBL] [Abstract][Full Text] [Related]